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ABSTRACT
Painful diabetic neuropathy (pDN) is charac-
terised by both sensory and affective distur-
bances, suggesting a complex bidirectional
relationship of neuropathic pain and mood
disorders. Data on pDN indicate that neuro-
pathic pain reduces quality of life, including
mood and physical and social functioning.
Depression and pain coping strategies such as
catastrophising and social support predict pain
severity. There is a significant and reciprocal
relationship between depressed mood and
increased pain. The key features of assessing
people with neuropathic pain in relation to
psychological aspects of their health are dis-
cussed in the context of management in a
tertiary pain management centre (The Walton
Centre, Liverpool, UK) including cognitive
behavioural interventions amongst others to
improve the quality of life in patients with pDN.
We consider psychological issues as a factor
influencing treatment and outcome in patients
with pDN.
Keywords: Acceptance and commitment
therapy; Anxiety; Cognitive behavioural
therapy; Depression; Painful diabetic
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Key Summary Points
Why carry out this study?
pDN can result in severe neuropathic pain
which is often be intractable. It has an
adverse effect on quality of life and social
functioning. Psychological factors play an
important role in pain perception.
The key features of evaluating people with
neuropathic pain in relation to
psychological aspects of their health are
discussed in the context of management
in a tertiary pain management centre. We
discuss cognitive behavioural
interventions to improve the quality of
life in patients with pDN.
What was learned from the study?
Pain reduction plays only a part of the
outcomes in a pain management
programme. Quality of life and
improvement in overall functioning are
key outcomes in psychological
interventions.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s asso-
ciated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.13352819
INTRODUCTION
It is well documented that pain is a significant
problem in primary care and neuropathic pain
represents a tremendous challenge worldwide.
It affects a huge proportion of the population,
14 million people in England, according to an
audit by the British Pain Society [1].
Clearly, only a proportion of these patients
have diabetic neuropathy or pain associated
with diabetes; however, whatever its aetiology,
pain can cause significant demands on the UK
National Health Service (NHS) [2]. Diabetic
peripheral polyneuropathy (also known as dia-
betic neuropathy) affects 50% of patients with
diabetes [3–5] and is an established risk factor
for poorer quality of life, and sleep, and symp-
toms of depression and anxiety [6]. Unfortu-
nately, it is also one of only three independent
risk factors for mortality in patients with type 2
diabetes mellitus [7].
There is a significant burden not only finan-
cially on health care but also for individuals in
terms of the impact on their lifestyles and quality
of life as well as theirmood [8]. It is of paramount
important that we address the needs of this
population of patients with pain symptoms
given that pain is often perceived as a mere
peripheral symptom to a broader disease process.
However, the burden on both the individual and
society is vast and requires significant attention.
The Walton Centre Pain Management Pro-
gramme (PMP) service has been in existence for
over 30 years and currently holds a registry of
patient data to track baseline physical function
and psychological distress as well as efficacy of
treatments. Since 2014 the PMP service has seen
approximately 4500 patients through multidis-
ciplinary assessment clinics and approximately
5% of these patients have a diagnosis of diabetic
neuropathy.
METHODS
This is a narrative review for the most part based
on a lecture provided at the 4th British Sympo-
sium on Diabetic Neuropathy (November 2019
held at theUniversity of Liverpool, UK) delivered
by Dr. Hannah Twiddy (Research Lead Clinical
Psychologist for the Pain Management Pro-
gramme, The Walton Centre), specifically per-
taining to the psychological services provided for
patients under the care of The Walton Centre
NHS Foundation Trust (Liverpool, UK) PMP. We
also undertook a brief literature review on pain-
ful diabetic neuropathy (pDN) andpsychological
interventions/pain management programmes
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using key search terms. Anumber of publications
were retrieved, covering the spectrum fromcross-
sectional studies, cohort studies, randomised
controlled trials (RCT), systematic, and thematic
reviews. This article is based on previously con-
ducted studies and does not contain any new
studies with human participants or animals per-
formed by any of the authors.
RESULTS
Current Management of pDN
pDN is a debilitating feature of diabetic neu-
ropathy which results in poor quality of life,
functional impairment and morbidity [9]. Cur-
rent international guidelines advocate the use
of pharmacotherapy targeting the pathomech-
anisms of pain generation in pDN. Moderate
improvements in pain are considered to be
approximately 30–50% pain relief, whereas a
good outcome is considered greater than 50%
pain relief [10]. Patients should be routinely
counselled about the effectiveness of neuro-
pathic pain agents in that only about one in
three people will achieve ‘good outcomes’ [11].
As a result a significant proportion of individu-
als have significant inadequately control pain
and as a result, poor functioning. There is very
little focus in international guidelines on
delivery of functional improvements through
psychological interventions.
For a further review of diabetic neuropathy
and treatment of pDN we recommend a review
of Iqbal et al. [11] and Alam et al. [10].
Psychosocial Impact in Diabetic
Neuropathy
There is a notable evidence base that discusses
the interference on physical and psychological
functioning of neuropathic pain in the context
and out of the context of diabetes [12, 13].
Indeed, mental comorbidity and sleep disorders
are factors associated with pDN and greater pain
intensity, more diabetes complications and
lower quality of life [14]. It is not uncommon to
assess patients in a tertiary centre and discover
comorbid psychological distress. Previous stud-
ies have highlighted the magnitude of psycho-
logical burden in this population [12, 13].
Vileikyte et al. demonstrated that diabetic neu-
ropathy (n = 338) is a risk factor for depression
due to pDN with increased pain, unsteadiness
and restrictions in activities of daily living sig-
nificantly predicting poorer outcomes on the
Hospital Anxiety and Depression subscale
(HADS-D) over 18 months [15]. Both depression
and anxiety are closely related to pain and pain
intensity [16, 17]. Additionally, people with
moderate-to-severe depressive symptoms are
more likely to develop pain [18]. Indeed, Collins
et al. suggested that anxiety disorders (32%)
were more prevalent than depression (22%) in
diabetes [19] which is replicated by other stud-
ies in pDN that found anxiety disorders to be as
prevalent as depression [20]. The intensity of
pain experienced in pDN directly impacts
function and increasing intensity of pDN is
associated with increased anxiety and depres-
sion. Clearly, there is a complex bidirectional
relationship of anxiety/depression and pDN
[20]. As clinical psychologists within the pain
management service we conceptualise pain as a
causative factor in many mood-related difficul-
ties. Often these factors do not work in a linear
fashion, and how we cope with pain can be
affected by pre-existing psychological vulnera-
bilities which forms a part of the assessment
process. Primary depressive or anxiety disorder
should be treated in the first instance before
embarking on psychological interventions for
pain; we refer individuals on to the relevant
mental health services once the primary issues
have been managed.
The Walton Centre PMP Assessment
in Clinic
The Walton Centre PMP meets the aims,
method, delivery and outcomes as per the Bri-
tish Pain Society’s guidelines for pain manage-
ment programmes for adults [21], the key points
of which are:
1. To improve participation in daily activities
of living, enhancing quality of life in people
with chronic pain
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2. A variety of methods being utilised by the
PMP for directly/indirectly producing beha-
viour modification, including cognitive and
behavioural therapy
3. The standard practice of outcome evalua-
tion such that stakeholders can ascertain
participant characteristics and the range of
improvements as a result of the PMP, in
both the short and longer term
The reduction or relief of pain is not a pri-
mary aim of treatment, although improvements
in pain are often reported [22, 23]. The primary
focus is to improve daily functioning even in
the absence of pain improvement and to shift
the behaviour of the participant from inade-
quate coping with pain and subsequently to
focus behaviour on individualised targets which
are more worthwhile [21].
Figure 1 and Table 1 highlight the key
domains and areas for assessment in patients
with persistent pain within the PMP service
[24]. Attendance is required at the assessment
clinic for 4 h and patients see four different
clinicians: a pain consultant, clinical psycholo-
gist, a physiotherapist and an occupational
therapist. The patient has about 45 min with
each clinician and at the end of the assessment
there is a multidisciplinary case conference
discussion about clinical presentation from the
different disciplinary perspectives. This includes
evaluation of medical, physiotherapy, social
mental health-related factors which may impact
their presentation. In concluding the clinic, a
personalised care package is discussed.
The impact of pain from the four areas
highlighted in Table 1 (i.e. biomedical, physio-
therapy, occupational therapy and psychology)
is significant with varying degrees of input from
each. It is important to collect information
about day to day life, relationships, employ-
ment and social life as much as pain intensity
and severity and to establish the significance of
mood-related factors in relation to loss of con-
fidence and self-esteem. A major concern of
patients is the notion that others disbelieve the
pain symptoms, symptoms are exaggerated or
are indicative of health anxiety or psychoso-
matic complaints. It can be difficult to concep-
tualise the pain for patients. The use of
metaphors and analogies can help individuals
to understand; it is also key to move away from
lists of symptoms such as burning, throbbing,
tingling pulsating and focus on—‘ok you have
those symptoms, tell me about how those
symptoms impact across these domains…’.
Psychologists working in chronic pain gather
information regarding an individual’s locus of
control [25]; how much does the individual feel
that they can be an agent in bringing about
change in their circumstances? This is broadly
more relevant to diabetes in terms of treatment
adherence and the ability and capability to
effectively manage physical wellbeing. In
chronic pain, it relates to self-efficacy, a feeling
of being effective in managing symptoms and
pain intensity [26]. The feeling that patients
have an internal locus of control can result in a
positive outlook of ‘I can bring about change to
my life’, as opposed to a negative outlook of ‘I
am going to wait here until something external
happens to help me to improve my life’. In
patients with an external locus of control and
low levels of pain-related self-efficacy, we may
consider that a number of factors could thwart
self-management approaches.
The PMP consists of both behavioural and
cognitive techniques; in addition, physical
exercise and education are also part of the pro-
cesses of delivery. Previous studies have shownFig. 1 Domains of impact and areas for assessment
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the effectiveness of PMP interventions. In a
meta-analysis of 11 studies, treatment gains
across pain perceptions were maintained at
12 months post-treatment and provided evi-
dence for long-term efficacy of PMP interven-
tions [27]. An early systematic review in 1999
[28], which was subsequently updated in 2012
as a Cochrane review [29], concluded that
Cognitive Behavioral Therapy (CBT) (on which
PMPs are based) is an effective intervention in
the armoury of the management of chronic
pain. Other studies have drawn similar conclu-
sions in mixed pain groups [30, 31]. As with
other studies the benefits are greatest in psy-
chological functioning measures. The residen-
tial INPUT Pain Management Unit reported
clinically significant improvement in pain and
psychological measures by 19–55% at post-
treatment and 17–44% at 9-month follow-up.
We detail psychological treatments and inter-
ventions in our PMP in more detail below.
Psychological Treatments
In the same manner that the assessment of
neuropathic pain takes a biopsychosocial
approach, the objective of psychologically led
interventions is not only the reduction in pain
but improvement in quality of life and mood-
related measures [32]; some measures included
are the Beck Depression Inventory (BDI-II),
chronic pain acceptance questionnaire (CPAQ),
pain-related self-efficacy questionnaire and the
pain catastrophising questionnaire. Patients
with both neuropathic and musculoskeletal
conditions attend for psychological interven-
tions at The Walton Centre PMP service. How-
ever, there are some factors, from a
Table 1 Key areas for biopsychosocial assessment [57]
Biomedical aspects Physiotherapy aspects Occupational
therapy aspects
Psychology aspects






Aetiology of pain What is an appropriate level of
physical activity?
Day to day routine
and structure
Impact of pain on mood
and activity
Physical prognosis Is there evidence of overly
restricted movement associated
with fear avoidance?
Aids and adaptations Pain beliefs and
behaviours—including
fear and avoidance
Need for further medical or
surgical interventions and
medication side effects
Are there outstanding issues




Is the pain medically
proportionate and/or makes
organic sense?
Pacing Treatment adherence in
other comorbidities
Iatrogenic distress
Motivation to change and
locus of control
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psychological perspective, that are relevant
when we consider the differences between the
underlying pain types. Patients with neuro-
pathic pain often describe allodynia, which
makes their presentation different than mus-
culoskeletal pain, as the pain is less predictable.
Musculoskeletal disease pain can be readily
amenable to physical exercise, whereas neuro-
pathic pain conditions including pDN are less
so, although some benefit may still occur with
exercise [33]. Modifications to the introduction
to the importance of physiotherapy, in terms of
helping people to modulate movement in neu-
ropathic pain conditions, can be vital [34].
Neuropathic pain needs to be considered in
the context of other comorbidities, such as
diabetes. Poor management of pain may itself
impact treatment adherence and management
of other physical conditions, whereas improv-
ing neuropathic pain may promote improve-
ments in glycaemic control [35]. For instance,
in a database analysis of approximately 4300
people with diabetes, patients who were adher-
ent to pDN medications were more adherent to
oral antidiabetic medications [36]. There is evi-
dence to suggest that there is poorer glycaemic
control in individuals with pDN [37]. Pai et al.
[37] showed that increased postprandial gly-
caemic exposure, as assessed by high glycated
haemoglobin (HbA1c) and near-normal fasting
plasma glucose levels, is associated with an
increased risk of pDN in type 2 diabetes.
Unfortunately, complications of diabetes are
also associated with psychological comorbidi-
ties. In a longitudinal cohort (n = 4623) of
patients with type 2 diabetes followed up from
2000–2002 to 2005–2007, major depression was
associated with significantly higher risks of
adverse microvascular outcomes [hazard ratio
1.36 (95% CI 1.05–1.75)] and adverse
macrovascular outcomes [1.24 (95% CI
1.0–1.54)] after adjustment for prior complica-
tions and clinical/demographic, and diabetes
self-care variables [38]. Similar findings were
also noted in the DIACET study conducted in an
over 65 years population in Japan (n = 4283)
where a higher Patient Health Questionnaire-9
(PHQ-9) was associated with increased odds
ratios for retinopathy, symptoms related to
peripheral neuropathy and autonomic
neuropathy, and end-stage renal disease
requiring dialysis after adjustment for clinical
and demographic factors and HbA1c [39]. A
systematic review (22 studies) and meta-analysis
(11 studies) of depression was associated with
an increased risk of both incident macrovascu-
lar (hazard ratio 1.38; 95% CI 1.30–1.47) and
microvascular disease (hazard ratio 1.33; 95% CI
1.25–1.41). Additionally, two studies
(n = 230,000) examining baseline diabetes
complications were suitable for meta-analysis
and showed an increased risk of incident
depressive disorder (hazard ratio 1.14; 95% CI
1.07–1.21).
There are two treatment modalities in PMP:
individual and group based. The format of
group-based PMPs follows the multidisciplinary
guidelines set out in the British Pain Society
guidelines. At The Walton Centre the two main
groups are run over either 16 days or 5 days over
6-week periods [40].
Acceptance and commitment therapy (ACT)
is a psychological modality that has been used
with increasing interest in chronic pain. It is
considered a third-wave of CBT and can be used
alongside more traditional CBT [41–43]. Tradi-
tional CBT approaches are focused on identify-
ing thoughts, feelings and behaviours that may
drive and maintain presenting psychological
difficulties. In the context of chronic pain the
focus is often around pain beliefs, e.g. the origin
of my pain is sinister or will harm me, and the
associated behavioural response. At The Walton
Centre, it is through supporting individuals to
identify unhelpful patterns and responses that
change to habituated patterns and subsequent
mood disturbance can be addressed. ACT uti-
lises acceptance and mindfulness strategies
along with commitment to behaviour change
to support individuals to develop psychological
flexibility; an individual’s ability to respond to
changing demands and alterations in emotions.
In the case of chronic pain, strategies are
focused on learning to live effectively and
alongside pain, an unpleasant experience,
through identifying value-led behaviour change
and mindful approaches. It can be provided on
a one-to-one basis if deemed necessary. A recent
study of 50 individuals with pDN based in Iran
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showed improved pain acceptance following
intervention after 3 months [41].
Considering the generalisability of psycho-
logical approaches to a primary care population,
a Brief Cognitive Behavioural Therapy for
Chronic Pain (Brief CBT-CP) delivered in a
community setting in the USA showed
improvements in pain intensity but impor-
tantly improvements in functional limitations
and pain-related efficacy outcomes [44]. Adap-
ted approaches such as the Brief CBT-CP are
eminently feasible in a community setting;
however, this will clearly require restructuring
of services and community and/or ambulatory
psychological input which are generally
underdeveloped [45].
Outcomes
Monitoring outcomes is key to assessing the
efficacy of self-management approaches in
chronic pain. At The Walton Centre a range of
psychometrics and physical function measures
are collected across domains [32]. These are
namely:
Beck’s Depression Inventory 2nd Edition (BDI-II)
consists of 21 items to assess the intensity of
depression in both clinical and non-clinical
populations [46]. The BDI-II was developed to
correspond to Diagnostic and Statistical Manual
of Mental Disorders IV (DSM-IV) criteria for
diagnosing depressive disorders. Given the high
prevalence of depression in individuals with
chronic pain and the negative outcomes
associated with such comorbidity, the impor-
tance of assessing depressive symptoms is
widely acknowledged by chronic pain
specialists.
Pain Catastrophising Scale (PCS) is a 13-item
self-report measure designed to assess catas-
trophic thoughts or feelings accompanying the
experience of pain [47]. The questionnaire uses
a 5-point scale ranging from 0 (not at all) to 4
(all the time). Pain catastrophising affects how
individuals experience pain. People who catas-
trophise tend to do three things. They ruminate
about their pain (‘I can’t stop thinking about
how much this hurts’), they magnify their pain
(e.g. ‘I’m afraid that something serious might
happen’), and they feel helpless to manage their
pain (‘there is nothing I can do to reduce the
intensity of my pain’).
Pain Self-Efficacy Questionnaire (PSEQ) is a
10-item questionnaire, developed to assess the
confidence people with ongoing pain have in
performing activities while in pain [48]. The
PSEQ is applicable to all persisting pain pre-
sentations, covering a range of functions,
including household chores, socialising, work,
as well as coping with pain without medication.
Table 2 Clinically meaningful change after PMP (The












Fig. 2 Key areas for consideration in clinical practice to
enhance a biopsychosocial approach
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Self-efficacy beliefs in people with chronic pain
have been assessed either by reference to con-
fidence in ability to perform specific tasks or
confidence in performing more generalised
constructs such as coping with pain.
Pain intensity is rated from 0 (no pain) to 10
(the most intense pain imaginable), taking into
Table 3 Highlights key areas with common ‘‘dos and don’ts’’: practical tips for medical practitioners to identify psy-
chosocial red flags
Practical tip Dos Don’ts
Develop rapport Listen and validate physical symptoms
Gently acknowledge the emotional impact
of living with pain and the broader
quality of life issues that could benefit
equally from attention
Advise the patient that persistent pains can
be caused by psychological problems or
trauma
Signpost Consider referring the patient on to
clinical health psychology services or ask
the GP to refer on to local service
provisions
Try to manage the patient’s psychological
issues independently if they need expert
opinion e.g. ‘‘exercise for a better mood’’,
‘‘think about all the positive things’’
Discharge them with no biopsychosocial
plan or reference in your clinical
correspondence to primary care that you
have observed mood-related difficulties in
the context of physical symptoms
Consider relevant systemic
factors and build up a picture
of holistic wellbeing
Enquire about treatment adherence in
other comorbid health conditions
Consider the age of the patient and the
specific difficulties pain may have on life
stage e.g. career/education/starting a
family




Ask patients to rate on a visual analogue
scale (0–10) the level of pain distress/
intensity and disability they experience—
make note if pain intensity is high but
distress is low and consider onward
referral to psychological services
Communication style and
language
Use accurate and clear language. Reduce
the risk of misunderstandings by
ensuring that the patient understands
accurately what you have advised
Ask the patient at the end if they need any
aspects to be clarified or anything has
caused undue concern
Avoid vivid and distressing analogies of
structural problems
Avoid unhelpful and potentially inaccurate
predictions of physical prognosis
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account how you have felt over the last week.
This commonly used method of rating pain
intensity is reliable and valid, and no one scale
consistently demonstrates greater responsive-
ness in detecting improvements associated with
pain treatment [49].
In addition to the measures stated above, a
number of tools have been utilised and vali-
dated to screen depression (PHQ-9 [50, 51],
HADS [52, 53]) and anxiety (HADS [52], Gen-
eralised Anxiety Disorder 7-item scale (GAD-7)
[54, 55]) in diabetes. However, there is a word of
caution: these instruments are not diagnostic
but should be used for screening purposes [56]
as elevated scores can be as a result of diabetes
symptomatology.
Table 2 highlights the average percentage of
patients who achieve clinically significant
change on PMPs (data based on more than 4500
patients from a clinical audit at The Walton
Centre—unpublished).
Whilst it is the job of a registered psycholo-
gist to identify specific psychological needs and
possible mental health diagnoses, there are
some things that non-psychological practition-
ers can helpfully do to help mitigate problems,
and also signpost on when necessary.
The take-home messages include validate
pain, which means acknowledge it is real and is
impacting on the individual’s quality of life.
Even though it might be peripheral to a broader
diagnosis that requires management by you a
non-pain specialist, it is key to validate the pain
experience. Consider the treatments offered—
are they all biomedical, do they need some
psychological input? Evaluate if the patient has
any psychosocial red flags (Fig. 2; Table 3). In
addition:
1. Are the patient’s expectations realistic?
2. Are there expectations of the complete
relief of pain?
3. Do they hope for this/a magical treatment?
4. Could language used by health-care profes-
sional possibly be feeding into
misperceptions?
5. Is a referral to mental health or multidisci-
plinary pain team appropriate?
CONCLUSION
It is important to consider the holistic presen-
tation of patients reporting persistent pain in
the context of pDN. Ongoing referrals may be
necessary to optimise outcomes, particularly if
psychosocial factors are at play. Pain reduction
is not the primary objective of pain manage-
ment approaches and patients should be
encouraged to consider issues of quality of life
and goals associated with such areas.
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The Beck depression inventory second edition (BDI-
II): psychometric properties in Icelandic student
and patient populations. Nord J Psychiatry.
2008;62(5):360–5.
47. Sullivan MJL, Bishop SR, Pivik J. The pain catas-
trophizing scale: development and validation. Psy-
chol Assess. 1995;7(4):524–32.
48. Nicholas MK. The pain self-efficacy questionnaire:
taking pain into account. Eur J Pain. 2007;11(2):
153–63.
49. Jensen MP, Karoly P. Self-report scales and proce-
dures for assessing pain in adults. Handbook of pain
assessment, 2nd ed. New York, NY, US: Guilford
Press; 2001. p. 15–34.
50. Acee AM. Detecting and managing depression in
type II diabetes: PHQ-9 is the answer! Medsurg
Nurs. 2010;19(1):32–8.
51. van Steenbergen-Weijenburg KM, de Vroege L,
Ploeger RR, et al. Validation of the PHQ-9 as a
screening instrument for depression in diabetes
patients in specialized outpatient clinics. BMC
Health Serv Res. 2010;10:235
52. Brennan C, Worrall-Davies A, McMillan D, Gilbody
S, House A. The hospital anxiety and depression
scale: a diagnostic meta-analysis of case-finding
ability. J Psychosom Res. 2010;69(4):371–8.
53. Lloyd CE, Dyer PH, Barnett AH. Prevalence of
symptoms of depression and anxiety in a diabetes
clinic population. Diabet Med. 2000;17(3):198–202.
54. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief
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